Ocular Therapeutix Company Leadership
| OCUL Stock | USD 9.77 0.12 1.21% |
About 80 percent of Ocular Therapeutix's insiders are selling. The analysis of insiders' sentiment of trading Ocular Therapeutix stock suggests that many insiders are terrified at this time. Ocular Therapeutix employs about 267 people. The company is managed by 18 executives with a total tenure of roughly 19 years, averaging almost 1.0 years of service per executive, having 14.83 employees per reported executive.
| Antony Mattessich CEO President CEO, Director |
| Christopher White President Senior Vice President Head of Business and Corporate Development |
Ocular Therapeutix's Insider Buying Vs Selling
20
Selling | Buying |
Latest Trades
| 2024-11-25 | Jeffrey S Heier | Disposed 2948 @ 9.01 | View | ||
| 2024-08-23 | Sanjay Nayak | Disposed 1832 @ 9.02 | View | ||
| 2024-05-23 | Sanjay Nayak | Disposed 2274 @ 5.84 | View | ||
| 2024-02-26 | Summer Road Llc | Acquired 930851 @ 7.52 | View | ||
| 2024-01-31 | Rabia Gurses Ozden | Disposed 7764 @ 4.95 | View |
Monitoring Ocular Therapeutix's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Ocular |
Ocular Therapeutix's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Ocular Therapeutix's future performance. Based on our forecasts, it is anticipated that Ocular will maintain a workforce of about 270 employees by January 2025.Ocular Therapeutix Management Team Effectiveness
The company has return on total asset (ROA) of (0.2237) % which means that it has lost $0.2237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7267) %, meaning that it created substantial loss on money invested by shareholders. Ocular Therapeutix's management efficiency ratios could be used to measure how well Ocular Therapeutix manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.34. The value of Return On Capital Employed is expected to slide to -0.4. At this time, Ocular Therapeutix's Asset Turnover is quite stable compared to the past year.The value of Common Stock Shares Outstanding is expected to slide to about 44.2 M. The value of Net Loss is expected to slide to about (67.1 M)
Ocular Therapeutix Workforce Comparison
Ocular Therapeutix is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 449. Ocular Therapeutix totals roughly 267 in number of employees claiming about 59% of equities under Health Care industry.
Ocular Therapeutix Profit Margins
The company has Profit Margin (PM) of (2.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.65) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.65.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.61 | 0.9096 |
|
|
Ocular Therapeutix Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ocular Therapeutix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ocular Therapeutix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ocular Therapeutix insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 1.5 | 6 | 4 | 995,200 | 28,339 |
| 2024-09-01 | 7.0 | 14 | 2 | 332,636 | 22,712 |
| 2024-06-01 | 1.0 | 2 | 2 | 566,666 | 23,900 |
| 2024-03-01 | 3.1429 | 22 | 7 | 5,103,943 | 55,876 |
| 2023-09-01 | 4.0 | 4 | 1 | 119,850 | 832.00 |
| 2023-03-01 | 2.2 | 11 | 5 | 1,607,646 | 44,571 |
| 2022-09-01 | 1.3333 | 4 | 3 | 160,000 | 156,667 |
| 2022-06-01 | 17.0 | 17 | 1 | 337,134 | 9,469 |
| 2021-12-01 | 2.3333 | 7 | 3 | 165,900 | 265,560 |
| 2021-06-01 | 6.0 | 6 | 1 | 108,000 | 10,000 |
| 2021-03-01 | 7.0 | 7 | 1 | 1,577,933 | 8,604 |
| 2020-12-01 | 1.0 | 6 | 6 | 416,264 | 837,208 |
| 2019-12-01 | 2.0 | 2 | 1 | 20,000 | 1,000.00 |
| 2017-12-01 | 4.0 | 8 | 2 | 518,893 | 189,393 |
| 2017-09-01 | 1.0 | 1 | 1 | 110,000 | 0.00 |
| 2016-09-01 | 0.6667 | 2 | 3 | 76,357 | 130,357 |
| 2015-12-01 | 2.0 | 2 | 1 | 21,363 | 0.00 |
| 2015-09-01 | 3.0 | 3 | 1 | 26,363 | 9,470 |
| 2015-06-01 | 0.5 | 6 | 12 | 79,896 | 2,291,491 |
| 2015-03-01 | 1.0 | 6 | 6 | 373,620 | 524,620 |
| 2014-09-01 | 0.5088 | 29 | 57 | 16,180,270 | 10,753,906 |
Ocular Therapeutix Notable Stakeholders
An Ocular Therapeutix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ocular Therapeutix often face trade-offs trying to please all of them. Ocular Therapeutix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ocular Therapeutix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Antony Mattessich | President CEO, Director | Profile | |
| Pravin MD | Executive Chairman | Profile | |
| Christopher White | Senior Vice President Head of Business and Corporate Development | Profile | |
| William Slattery | Vice Relations | Profile | |
| Todd Anderman | Chief Secretary | Profile | |
| William II | Vice Marketing | Profile | |
| Peter MD | Chief Officer | Profile | |
| Donald Notman | Chief Officer | Profile | |
| Philip Esq | General Counsel | Profile | |
| Rabia MD | Chief Officer | Profile | |
| Peter Jarrett | Chief Officer | Profile | |
| Tracy Smith | Vice Resources | Profile | |
| Jeffrey MD | Chief Officer | Profile | |
| Philip Strassburger | G Counsel | Profile | |
| Scott Corning | VP Commercial | Profile | |
| Steve Meyers | Senior Commercial | Profile | |
| KarenLeigh MBA | Senior Operations | Profile | |
| Sanjay MBBS | Chief Officer | Profile |
About Ocular Therapeutix Management Performance
The success or failure of an entity such as Ocular Therapeutix often depends on how effective the management is. Ocular Therapeutix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ocular management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ocular management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.89) | (0.84) |
Ocular Therapeutix Workforce Analysis
Traditionally, organizations such as Ocular Therapeutix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ocular Therapeutix within its industry.Ocular Therapeutix Manpower Efficiency
Return on Ocular Therapeutix Manpower
| Revenue Per Employee | 218.9K | |
| Revenue Per Executive | 3.2M | |
| Net Loss Per Employee | 302.4K | |
| Net Loss Per Executive | 4.5M | |
| Working Capital Per Employee | 739.1K | |
| Working Capital Per Executive | 11M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.